Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003084854 | SCV003483361 | uncertain significance | not provided | 2022-05-18 | criteria provided, single submitter | clinical testing | This variant disrupts the p.Arg199 amino acid residue in PYCR2. Other variant(s) that disrupt this residue have been observed in individuals with PYCR2-related conditions (PMID: 27130255, 30829456), which suggests that this may be a clinically significant amino acid residue. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This missense change has been observed in individual(s) with leukodystrophy (PMID: 30829456). This variant is present in population databases (rs376952965, gnomAD 0.01%). This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 199 of the PYCR2 protein (p.Arg199Gln). |
Gene |
RCV003084854 | SCV004169118 | likely pathogenic | not provided | 2023-10-24 | criteria provided, single submitter | clinical testing | Previously identified in the homozygous state in an individual with hypomyelinating leukodystrophy 10; however, this individual was also heterozygous for a variant in another gene that may have contributed to the phenotype (PMID: 30829456); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 37563452, 30829456) |
Molecular Genetics laboratory, |
RCV003084854 | SCV004031281 | pathogenic | not provided | 2021-11-08 | no assertion criteria provided | clinical testing |